Updating results

Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma ID1352

In development [GID-TA10319] Expected publication date: TBC

Technology appraisal guidance In development

Lurbinectidin for treating advanced platinum-resistant ovarian cancer ID1340

In development [GID-TA10313] Expected publication date: TBC

Technology appraisal guidance In development

KTE-C19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 ID1336

In development [GID-TA10316] Expected publication date: TBC

Technology appraisal guidance In development

Epilepsies in adults: diagnosis and management update (Please see Epilepsies in children, young people and adults)

In development [GID-NG10110] Expected publication date: 07 April 2021

NICE guideline In development

Pembrolizumab with epacadostat for untreated malignant melanoma ID1423

In development [GID-TA10330] Expected publication date: TBC

Technology appraisal guidance In development

Abemaciclib for treating KRAS mutation-positive non-small-cell lung cancer after platinum-based chemotherapy ID1147

In development [GID-TA10343] Expected publication date: TBC

Technology appraisal guidance In development

Avelumab for treating non-small-cell lung cancer after platinum-based chemotherapy [ID1146]

In development [GID-TA10341] Expected publication date: TBC

Technology appraisal guidance In development

Safe prescribing and withdrawal management of prescribed drugs associated with dependence and withdrawal

In development [GID-NG10141] Expected publication date: 17 November 2021

NICE guideline In development

Managing common infections - antimicrobial prescribing guidelines

In development [GID-NG10050] Expected publication date: TBC

NICE guideline In development

Neonatal parenteral nutrition

In development [GID-NG10037] Expected publication date: 26 February 2020

NICE guideline In development

Heart valve disease presenting in adults: investigation and management

In development [GID-NG10122] Expected publication date: 20 May 2021

NICE guideline In development

Antenatal care for uncomplicated pregnancies update

In development [GID-NG10096] Expected publication date: 21 April 2021

NICE guideline In development

Secukinumab for treating non-radiographic axial spondyloarthritis [ID1419]

In development [GID-TA10457] Expected publication date: 19 August 2020

Technology appraisal guidance In development

Tinnitus: assessment and management

In development [GID-NG10077] Expected publication date: 11 March 2020

NICE guideline In development

Diabetes in pregnancy: management from preconception to the postnatal period

In development [GID-NG10158] Expected publication date: TBC

NICE guideline In development

Diabetes (type 1 and type 2) in children and young people: diagnosis and management (update)

In development [GID-NG10161] Expected publication date: TBC

NICE guideline In development

Type 1 diabetes in adults: diagnosis and management (update)

In development [GID-NG10159] Expected publication date: TBC

NICE guideline In development

Type 2 diabetes in adults: management (update)

In development [GID-NG10160] Expected publication date: TBC

NICE guideline In development

Durvalumab for untreated EGFR-negative, ALK-negative non-small-cell lung cancer ID1331

In development [GID-TA10318] Expected publication date: TBC

Technology appraisal guidance In development

Atezolizumab with nab-paclitaxel for neoadjuvant treatment of early triple negative breast cancer [ID1574]

In development [GID-TA10531] Expected publication date: TBC

Technology appraisal guidance In development

Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]

In development [GID-TA10542] Expected publication date: TBC

Technology appraisal guidance In development

Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma [ID1589]

In development [GID-TA10481] Expected publication date: 23 September 2020

Technology appraisal guidance In development

TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices [ID1440]

In development [GID-TA10370] Expected publication date: TBC

Technology appraisal guidance In development

Naldemedine for treating opioid-induced constipation ID1189

In development [GID-TA10291] Expected publication date: 05 June 2020

Technology appraisal guidance In development

KTE-X19 for treating relapsed or refractory mantle cell lymphoma ID1313

In development [GID-TA10312] Expected publication date: 06 December 0021

Technology appraisal guidance In development

Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]

Technology appraisal [TA582] Published date: 24 May 2019

Technology appraisal guidance In development

Colorectal cancer: diagnosis and management (update)

In development [GID-NG10060] Expected publication date: 29 January 2020

NICE guideline In development

Sapropterin for treating phenylketonuria [ID1475]

In development [GID-TA10378] Expected publication date: TBC

Technology appraisal guidance In development

SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals)

In development [GID-MT526] Expected publication date: TBC

Medical technologies guidance In development

Atezolizumab with cobimetinib and vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma [ID1674]

In development [GID-TA10543] Expected publication date: TBC

Technology appraisal guidance In development

Luspatercept for treating anaemia caused by myelodysplastic syndromes [ID1550]

In development [GID-TA10508] Expected publication date: TBC

Technology appraisal guidance In development

Mental wellbeing at work

In development [GID-NG10140] Expected publication date: 18 August 2021

NICE guideline In development

Lisocabtagene maraleucel for treating large B-cell lymphoma after at least 2 therapies ID1444

In development [GID-TA10477] Expected publication date: TBC

Technology appraisal guidance In development

ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]

In development [GID-TA10489] Expected publication date: 23 September 2020

Technology appraisal guidance In development

Tezacaftor and ivacaftor combination therapy for treating cystic fibrosis with the F508del mutation [ID1303]

In development [GID-TA10277] Expected publication date: TBC

Technology appraisal guidance In development

Leg ulcer infection: antimicrobial prescribing

In development [GID-NG10133] Expected publication date: 11 February 2020

Antimicrobial prescribing guideline In development

Impetigo: antimicrobial prescribing

In development [GID-NG10134] Expected publication date: 11 February 2020

Antimicrobial prescribing guideline In development

Clostridium difficile infection: antimicrobial prescribing

In development [GID-NG10144] Expected publication date: 30 September 2020

Antimicrobial prescribing guideline In development

Atezolizumab with nab-paclitaxel for treating PD L1-positive, triple-negative, advanced breast cancer [ID1522]

In development [GID-TA10433] Expected publication date: TBC

Technology appraisal guidance In development

Encorafenib in dual or triple therapy for previously treated BRAF V600E mutation-positive metastatic colorectal cancer [ID1598]

In development [GID-TA10496] Expected publication date: 21 October 2020

Technology appraisal guidance In development

Erenumab for preventing migraine [ID1188]

In development [GID-TA10302] Expected publication date: TBC

Technology appraisal guidance In development

Osteoarthritis: care and management (update)

In development [GID-NG10127] Expected publication date: 25 August 2021

NICE guideline In development

Ozanimod for treating relapsing-remitting multiple sclerosis [ID1294]

In development [GID-TA10299] Expected publication date: 22 July 2020

Technology appraisal guidance In development

Bempedoic acid for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID1515]

In development [GID-TA10534] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab for treating unresectable advanced oesophageal cancer when standard chemotherapy has failed [ID1249]

In development [GID-TA10222] Expected publication date: 06 January 2021

Technology appraisal guidance In development

Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm ID1556

In development [GID-TA10482] Expected publication date: 24 March 2021

Technology appraisal guidance In development

Acne Vulgaris: Management

In development [GID-NG10109] Expected publication date: 13 January 2021

NICE guideline In development

Human and animal bites: antimicrobial prescribing

In development [GID-NG10137] Expected publication date: 30 June 2020

Antimicrobial prescribing guideline In development

Peezy Midstream for urine collection (SUSPENDED)

In development [GID-MT538] Expected publication date: TBC

Medical technologies guidance In development

Atezolizumab with gemcitabine and carboplatin for treating metastatic urothelial bladder cancer [ID1206]

In development [GID-TA10202] Expected publication date: TBC

Technology appraisal guidance In development